Jazz Pharmaceuticals plc
$241.55
+1.18 (+0.49%) · delayed · Nov 13, 2026
Five-year price
52w $156.95 to $266.38
- Market cap
- $15.5B
- Enterprise value
- $19.5B
- P/E
- —
- 81.3× on 3y avg EPS
- EV / EBIT
- —
- FCF yield
- 8.4%
- ROIC
- −4.1%
- Debt / equity
- 1.24
- Piotroski F
- 5/9
Value scorecard · FY2025
Does it pass the value tests?
Quality
33
- ○ROIC > 12% (5y avg)5y avg ROIC 2.6%
- ○ROE > 15% (5y avg)5y avg ROE 0.2%
- ○Stable operating marginsMargin volatility 10.3% (σ, 5y)
- ●Earnings convert to cashFCF / net income 250% (5y avg)
- ●Growing revenueRevenue CAGR 5y 12.5%
- ○Shrinking share countDiluted shares 7.9% over 5y
Value
n/a
- –P/E below 15P/E n/a
- –EV/EBIT below 12EV/EBIT n/a
- ●FCF yield above 6%FCF yield 8.4%
- –Price below Graham NumberGraham Number n/a
- ○P/B below 3P/B 3.6
Safety
20
- ○Debt / equity below 0.5D/E 1.24
- ○Debt payable in < 4 yrs of earningsNet debt $4.0B
- ○Interest coverage > 8xCoverage -1.7x
- ●Current ratio > 1.5Current ratio 1.86
- ○Piotroski F-score ≥ 6F-score 5/9
Graham Defensive
14
- ●Adequate size (revenue > $2B)Revenue $4.3B
- ○Strong condition (current ratio ≥ 2)Current ratio 1.86
- ○Earnings stability (no loss, 10y)10 years of data
- ○Uninterrupted dividendsDividends paid every year on record
- ○Earnings growth ≥ 33% (10y, 3y avgs)EPS growth -59%
- ○Moderate P/E (≤ 15 on 3y avg EPS)P/E (3y avg) 81.3
- ○P/E × P/B ≤ 22.5Product 292.0
Valuation lab
What do you have to believe?
At $241.55, the market is pricing in about 1.8% annual free-cash-flow growth for the next decade (9% discount rate, 2.5% terminal growth).
Starting cash flow
Net debt $4.0B · 64M shares · 5y revenue CAGR 12.5%
Intrinsic value
$642.79
Price
$241.55
Margin of safety
62%
What the price implies
The market is paying for 1.8% annual cash-flow growth for 10 years at a 9.0% discount rate.
Terminal value share
65% of the value sits beyond year 10.
Financial statements
A decade of the record.
USD millions · fiscal years · source: SEC 10-K XBRL
| Line item | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,488 | 1,619 | 1,891 | 2,162 | 2,364 | 3,094 | 3,659 | 3,834 | 4,069 | 4,268 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Operating income | 592 | 529 | 615 | 532 | 378 | 170 | (66) | 579 | 717 | (430) |
| Operating margin | 39.8% | 32.7% | 32.5% | 24.6% | 16.0% | 5.5% | -1.8% | 15.1% | 17.6% | -10.1% |
| Pre-tax income | 532 | 441 | 529 | 454 | 275 | (113) | (373) | 298 | 470 | (628) |
| Income tax | 135 | (48) | 80 | (73) | 34 | 216 | (159) | (120) | (91) | (272) |
| Net income | 397 | 488 | 447 | 523 | 239 | (330) | (224) | 415 | 560 | (356) |
| EPS (diluted) | 6.41 | 7.96 | 7.30 | 9.09 | 4.22 | -5.52 | -3.58 | 6.10 | 8.65 | -5.84 |
| Diluted shares | 62 | 61 | 61 | 58 | 57 | 60 | 63 | 72 | 66 | 61 |
Who owns it